Ads
related to: empagliflozin indication of diabetes drug- JARDIANCE Dosing Data
Dosing Considerations And Data
For Healthcare Professionals.
- JARDIANCE Clinical Data
Clinical Trial Data Presented For
US Healthcare Professionals.
- JARDIANCE Guidelines
Learn About JARDIANCE Guidelines
For Healthcare Professionals
- JARDIANCE Safety Data
Safety & Warning Information For
US Healthcare Professionals.
- JARDIANCE Dosing Data
Search results
Results from the WOW.Com Content Network
The risk of empagliflozin-associated euglycemic diabetic ketoacidosis may be higher in the setting of illness, dehydration, surgery, and/or alcohol consumption. [38] It is also seen in type 1 diabetes who take empagliflozin, which notably is an unapproved or "off-label" use of the medication. [39]
Empagliflozin, approved in the United States in August 2014, under the brand name Jardiance by Boehringer Ingelheim. [30] Of the gliflozins, empagliflozin and tofogliflozin have the highest specificity for SGLT2 inhibition. [1] This oral medicine for type 2 diabetes has been shown to reduce the risk of cardiovascular death. [31]
In the European Union empagliflozin/metformin is indicated in adults aged 18 years and older with type 2 diabetes mellitus as an adjunct to diet and exercise to improve glycemic control: [5] in adults inadequately controlled on their maximally tolerated dose of metformin alone; [ 5 ]
The sodium glucose co-transporter-2 inhibitor empagliflozin is part of a larger class of drugs being tested for their ability to reduce blood glucose levels in Type 2 diabetic adults by blocking ...
A recent study has shown that people who take SGLT-2 inhibitors for type 2 diabetes management have a 35% lower diabetes risk, overall. A diabetes drug may help prevent dementia, new research ...
Eli Lilly and Boehringer Ingelheim Pharmaceuticals said today that the Food and Drug Administration rejected empagliflozin, the most recent drug to come out of the companies' diabetes partnership.
Ads
related to: empagliflozin indication of diabetes drug